XML 46 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segments (Tables)
12 Months Ended
Dec. 31, 2024
Segments  
Schedule of segment net loss by significant expense category

Year Ended December 31, 

    

2024

    

2023

    

2022

Compensation and benefits, excluding stock-based compensation

$

7,438

 

$

6,737

 

$

7,239

Stock-based compensation

3,003

 

2,148

 

2,691

Drug manufacturing

2,485

 

2,195

 

11,213

Clinical trial

4,148

 

2,716

 

3,159

Outside general and administrative

3,101

 

2,703

 

2,978

Facilities and insurance

3,219

 

3,160

 

3,342

Other segment items (1)

4,154

 

3,748

 

1,943

Total segment expense

27,548

 

23,407

 

32,565

Non-operating income and expense, net

34,745

 

3,622

 

8,742

Net loss

$

62,293

 

$

27,029

 

$

41,307

(1)Includes consulting, non-clinical research and laboratory supplies.